Third Rock Ventures and Parse Biosciences announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs)...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy, announced the official opening and ribbon c...
-Atomic launches today as a first-of-its-kind service offering for MedTech startups built to bridge the gap between breakthrough concepts and investor-re...
- March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, announced that the U.S...
Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS (amyotrophic ...
Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in ...
Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet fut...
Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety pr...
Fibro dT platform offers a high-capacity solution for mRNA purification with chromatography cycle times under 15 minutes. Sustainable pe...
Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastat...
Pfizer Inc. announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery...
ChemDiv, a global provider of integrated drug discovery solutions, announced the extension of its Chemistry, Manufacturing and Controls (CMC) servi...
Chromatin Bioscience is pleased to announce an ongoing research collaboration with Purespring Therapeutics, a precision nephrology company leading the de...
- Robust responses observed in heavily pre-treated patients with a 68% ORR for 1.6 mg/kg in second-line setting -Compelling activity in patients with ...
© 2026 Biopharma Boardroom. All Rights Reserved.
